Kuala Lumpur, Malaysia, 16 June 2025 – The Minos™ Abdominal Aortic Stent Graft and Delivery System (Minos™), developed by MicroPort® Endovastec™, was recently used in its first post-market implantation in Malaysia.
The procedure was performed on a 78-year-old male patient diagnosed with an abdominal aortic aneurysm complicated by severe calcification. Post-operative results confirmed proper stent positioning and improved blood flow.
Minos™ is designed for patients with abdominal aortic aneurysms that have a proximal neck length ≥15 mm. It features a low-profile 14F delivery system with a modular stent structure, offering flexible deployment options for complex anatomies. The device is currently in clinical use across more than 25 countries.
This case further expands MicroPort®’s footprint in Malaysia, following the local adoption of its thoracic aortic solutions, including the Castor™ Branched Aortic Stent Graft System. It highlights the company’s ongoing commitment to bringing innovative endovascular solutions to global markets.
About MicroPort® Endovastec™
Founded in 2012, MicroPort® Endovastec™ (Shanghai MicroPort Endovascular MedTech Group Co., Ltd.; SSE: 688016), an associated company of MicroPort® (MicroPort Scientific Corporation, HKEX: 00853), is a global medical device company focusing on R&D, manufacturing, and commercialization of aortic and peripheral vascular interventional devices. MicroPort® Endovastec™'s product portfolio includes thoracic and abdominal aortic stent grafts, stent grafts in surgical operation, peripheral vascular stents, and drug-coated PTA balloon catheters. MicroPort® Endovastec™ breaks barriers and accelerates innovation to provide trustworthy and universal access to state-of-the-art solutions for prolonging and reshaping all lives, and to build a leading enterprise of emerging technologies in great vessel surgery and peripheral vascular medicine.
More information is available at: www.endovastec.com/en